Bayesian Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bayesian Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,207	Closed	-$477K	–	1083
2023 Q2	$477K	Buy	+13,207	New	+$544K	0.05%	419
2022 Q3	–	Sell	-16,493	Closed	-$1.11M	–	1082
2022 Q2	$1.11M	Buy	+16,493	New	+$1.05M	0.21%	131

Other funds holding MRTX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bayesian Capital Management's MRTX Position: Q3 2023 in Review

Bayesian Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 13,207 shares — an estimated $477K sold.

Bayesian Capital Management first reported a position in MRTX in Q2 2022 and held it in 2 quarters. The position peaked at $1.11M in Q2 2022. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

Bayesian Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bayesian Capital Management sold 13,207 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $477K.
Bayesian Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Bayesian Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $1.11M in Q2 2022.
213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bayesian Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.